Cartagenia announced today that it and Qiagen’s bioinformatics business are part of a consortium that has received €1.4 million ($1.7 million) in funding from a European funding initiative to support the development of software tools for personalized genetic analysis of cancer variants.
The Lungcadia program will combine the technologies and expertise of Cartagenia, Qiagen, and the Institute of Pathology at Hannover Medical School and will focus on lung cancer as a disease model, but the partners aim to make the results applicable to other types of cancer. The project has received the funding from the EuroTransBio initiative, which supports biotech collaborations in Europe.
{iframe}http://www.genomeweb.com/informatics/cartagenia-qiagen-part-cancer-analysis-consortium-receiving-17m{/iframe}